Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients (RESEARCH)

AstraZeneca

Status: Completed

Conditions: Hypercholesterolaemia

Study type: Observational

Funder types: Industry

Identifiers

NCT00695539

NIS-CGR-CRE-2007/1

Details and patient eligibility

About

This is a single-arm, phase IV, open-label, prospective, non interventional study to evaluate the efficacy, tolerability and safety of rosuvastatin administered for 24 weeks in approximately 900 Greek subjects with hypercholesterolemia under normal clinical practice.

Enrollment: 810 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hypercholesterolaemia who are already in treatment with rosuvastatin according to the approved SPC for no longer than 1 month prior to study entry
• Patients that are able to read, understand and sign the Patient Information & Consent Form
• Patients that are willing to comply with all study requirements

Exclusion criteria

• Patients that are likely not to comply with all study requirements
• Patients that currently participate or have participated in a 3 months period prior to study entry in another clinical trial
• Female of child bearing potential that do not use a reliable method of contraception. Pregnancy or lactation.
• Patients that meet any of the contraindications described in the approved SPC